Completed $2M Series A Extension

Completed financing to provide runway through the end of 2025. Primary use of funds is our FDA IND (investigative new drug) application for our Phase 2b/3 clinical trial in Parkinson's Disease Dementia and completion of animal testing for our pre-clinical drugs.\r\n\r\nWe will be oversubscribing the round by $1M-$2M by mid-January 2025 to provide additional runway and to fund long term toxicity studies on 1 of our preclinical drugs.